First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer (Q38247493)
Jump to navigation
Jump to search
scientific article published on 09 September 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer |
scientific article published on 09 September 2014 |
Statements
1 reference
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer (English)
1 reference
Laleh Amiri-Kordestani
1 reference
Suparna Wedam
1 reference
Lijun Zhang
1 reference
Shenghui Tang
1 reference
Amy Tilley
1 reference
Amna Ibrahim
1 reference
Robert Justice
1 reference
Richard Pazdur
1 reference
Patricia Cortazar
1 reference
9 September 2014
1 reference
1 reference
Identifiers
1 reference